Alzamend Neuro is developing two therapeutic drug candidates, AL001 and ALZN002, utilizing patented ionic cocrystal technology and a cell-based therapeutic vaccine to treat Alzheimer's disease and related dementias. The company aims to provide effective treatments for over 6.5 million Americans suffering from Alzheimer's, addressing the urgent need for viable medical solutions in this growing patient population.
Funding
Funding not disclosed
Founders
Product
Problem
Current treatments for Alzheimer's disease primarily address symptoms, failing to target the underlying causes of neurodegeneration. Existing anti-amyloid treatments have shown limited success and can induce neural inflammation, potentially exacerbating the disease. There is a need for therapies that can effectively modulate the immune system to combat toxic amyloid-beta (Aβ) accumulation without causing harmful side effects.
Solution
Alzamend Neuro is developing immunomodulatory vaccines and ionic cocrystal technology to treat Alzheimer's, Bipolar disorder, Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD). ALZN002, a cell-based therapeutic vaccine, uses a mutant-peptide sensitized cell to restore the immunological system's ability to combat Alzheimer's. AL001, an ionic cocrystal technology, delivers lithium through a combination of lithium, proline, and salicylate. These therapies aim to provide safe and effective treatments by targeting the underlying causes of neurodegeneration and modulating the immune response without causing excessive inflammation.
Target Audience
The primary target audience includes individuals suffering from Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD), as well as healthcare providers and researchers seeking disease-modifying treatments.
Features
- AL001: Patented ionic cocrystal technology for delivering lithium, proline, and salicylate
- ALZN002: Cell-based therapeutic vaccine using a mutant-peptide sensitized cell
- Immunomodulatory approach to target toxic amyloid-beta (Aβ) molecules
- Potential to slow memory impairment and cognitive decline
- Designed to minimize unwanted autoimmune reactions
- Phase II clinical trials for AL001 in Alzheimer's, MDD, PTSD and Bipolar disorder